Core Viewpoint - Investors in uniQure N.V. have the opportunity to lead a securities fraud lawsuit against the company due to alleged violations of the Securities Exchange Act of 1934, specifically related to misleading statements about FDA approval and BLA timelines [1] Group 1: Lawsuit Details - The Schall Law Firm is reminding investors of a class action lawsuit against uniQure N.V. for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1] - The class period for the lawsuit is defined as between September 24, 2025, and October 31, 2025, during which investors are encouraged to contact the firm before April 13, 2026 [1] - The lawsuit claims that uniQure made false and misleading statements regarding its ability to secure full FDA approval for its Pivotal Study and misrepresented the likelihood of delaying its BLA timeline [1] Group 2: Investor Impact - Investors who purchased uniQure's securities during the class period reportedly suffered damages when the truth about the company's misleading statements was revealed [1] - The Schall Law Firm specializes in securities class action lawsuits and represents investors globally, indicating a focus on protecting shareholder rights [1]

Core Viewpoint - The SLM Corporation, also known as Sallie Mae, is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with a focus on misleading statements regarding delinquency rates in private education loans [1][3]. Group 1: Class Action Lawsuit Details - Investors in SLM securities from July 25, 2025, to August 14, 2025, can seek appointment as lead plaintiff by February 17, 2026 [1]. - The lawsuit, titled Zappia v. SLM Corporation, claims that SLM and its executives made false statements and failed to disclose significant increases in early-stage delinquencies [3][4]. - A report from TD Cowen on August 14, 2025, indicated that July 2025 delinquencies rose by 49 basis points month-over-month, contradicting SLM's CFO's earlier assurances about normal seasonal trends [4]. Group 2: Allegations Against SLM - The lawsuit alleges that SLM overstated the effectiveness of its loss mitigation and loan modification programs, as well as the overall stability of its private education loan delinquency rates [3]. - Following the TD Cowen report, SLM's stock price dropped by approximately 8%, reflecting investor reaction to the disclosed delinquency issues [4]. Group 3: Legal Process and Firm Background - The Private Securities Litigation Reform Act of 1995 allows any investor who suffered losses during the class period to seek lead plaintiff status, which enables them to direct the lawsuit on behalf of all class members [5]. - Robbins Geller Rudman & Dowd LLP, the law firm representing the investors, is recognized as a leading firm in securities fraud litigation, having recovered over $916 million for investors in 2025 alone [6].

RADNOR, Pa.--(BUSINESS WIRE)---- $PINS #classaction--Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities fraud class action lawsuit has been filed against Kyndryl Holdings, Inc. (Kyndryl) (NYSE: KD) on behalf of those who purchased or acquired Kyndryl securities between August 7, 2024, and February 9, 2026, inclusive. The lawsuit is filed in the United States District Court for the Eastern District of New York and is captioned Brander v. Kyndryl Holdings, Inc., et al, Case ...

Core Viewpoint - A securities fraud class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for allegedly making false and misleading statements regarding its drug setrusumab during the class period from August 3, 2023, to December 26, 2025 [2][5]. Summary by Relevant Sections Lawsuit Details - The lawsuit is filed in the United States District Court for the Northern District of California, under the case name Bailey v. Ultragenyx Pharmaceutical Inc., et al, Case No. 3:26-cv-01097 [2]. - Investors have until April 6, 2026, to file for lead plaintiff status [2][5]. Allegations - The complaint alleges that Ultragenyx misrepresented its knowledge about the effects of setrusumab on patients with Osteogenesis Imperfecta and downplayed the risks associated with the Phase III Orbit study [3]. - It is claimed that Ultragenyx's optimism regarding the study results was unfounded, as the Phase II results lacked a placebo control group, raising concerns about the validity of the reported reduction in annualized fracture rate (AFR) [3]. - The lawsuit asserts that the positive statements made by the company regarding its business and prospects were materially misleading [3]. Investor Actions - Investors affected by the alleged fraud are encouraged to contact Kessler Topaz Meltzer & Check, LLP for recovery options at no cost [5][6]. - The lead plaintiff process allows investors to seek representation in the lawsuit, with the deadline set for April 6, 2026 [4][6]. Law Firm Information - Kessler Topaz Meltzer & Check, LLP is a prominent law firm specializing in securities-fraud class actions and has a history of significant recoveries in securities litigation [8].

Core Viewpoint - A class action lawsuit has been filed against Kyndryl Holdings, Inc. and certain senior executives for securities fraud following significant stock drops due to potential violations of federal securities laws [1][3]. Company Overview - Kyndryl is a provider of enterprise technology services, offering advisory, implementation, and managed service capabilities to customers in over 60 countries. It is recognized as the world's largest IT infrastructure services provider [4]. Allegations - The lawsuit alleges that Kyndryl misrepresented its cash management practices, including the drivers of its adjusted free cash flow metric and the effectiveness of its internal controls over financial reporting for FY2025 and the first three quarters of FY2026 [5]. Stock Performance - On February 9, 2026, Kyndryl announced a delay in releasing its fiscal Q3 2026 financial statement due to an accounting review of its cash management practices, which led to the immediate departures of its CFO and General Counsel. This announcement resulted in a stock price drop of $12.90 per share, or 55%, from a closing price of $23.49 on February 8, 2026, to $10.59 on February 9, 2026 [6][7]. Legal Proceedings - Investors have until April 13, 2026, to request to be appointed to lead the case, which is pending in the U.S. District Court for the Eastern District of New York under the caption Brander v. Kyndryl Holdings, Inc., et al., No. 1:26-cv-00782 [3].

Core Viewpoint - Paysafe Limited is facing a class action lawsuit for securities fraud, with allegations of false and misleading statements regarding its financial health and risk exposure [1]. Summary by Relevant Sections Company Overview - Paysafe Limited (NYSE: PSFE) is under scrutiny for potential violations of the Securities Exchange Act of 1934, specifically §§10(b) and 20(a) and Rule 10b-5 [1]. Legal Proceedings - The Schall Law Firm is leading the class action lawsuit, encouraging investors who purchased Paysafe securities between March 4, 2025, and November 12, 2025, to participate before the deadline of April 7, 2026 [1]. - The lawsuit claims that Paysafe had significant exposure to a high-risk client in its e-commerce business, which was not disclosed to investors [1]. Financial Misrepresentation - Allegations include that Paysafe understated its credit loss reserves and/or write-offs, and failed to disclose higher risk Merchant Category Codes [1]. - The company's public statements are claimed to have been false and materially misleading throughout the class period, leading to investor damages when the truth was revealed [1].

Core Insights - Kessler Topaz Meltzer & Check, LLP is investigating potential violations of federal securities laws on behalf of investors of Commvault Systems, Inc. [1] Financial Performance - Commvault reported a 40% growth in SaaS ARR to $364 million for the third quarter of fiscal 2026, which ended on December 31, 2025 [2] - The growth rate of 40% represents a significant deceleration from the 56% growth reported for the second quarter of fiscal 2026 [2] Stock Market Reaction - Following the financial results announcement, Commvault's stock price fell by $40.23 per share, approximately 31.1%, from a closing price of $129.36 on January 26, 2026, to $89.13 on January 27, 2026 [3]

Core Viewpoint - Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against uniQure N.V. on behalf of investors who purchased shares during a specified class period, alleging that the company made materially false and misleading statements regarding its drug AMT-130 and its regulatory approval process [1][11]. Company Overview - uniQure N.V. is a biotechnology company focused on developing gene therapies for rare diseases, including Huntington's disease (HD) [3]. - The company's leading drug candidate, AMT-130, aims to slow the progression of HD, a fatal genetic disorder with no existing cure [4]. Clinical Trials and FDA Interaction - uniQure completed patient enrollment for two ongoing Phase I/II clinical trials for AMT-130, known as the Pivotal Study, in March 2022 [4]. - The FDA had previously agreed that the Pivotal Study would not include a placebo comparator, allowing results to be compared to an external historical dataset, ENROLL-HD, for potential BLA submission [5]. Investor Communication and Stock Performance - On September 24, 2025, uniQure announced topline results from the Pivotal Study, leading to a significant increase in share price from $13.66 to $47.50, a nearly 250% rise [8]. - By October 29, 2025, shares were trading above $70.00, prompting the company to offer over 5.7 million shares to capitalize on the increased valuation, generating approximately $345 million [9]. Disclosure of Regulatory Challenges - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that the data from the Pivotal Study would be adequate for BLA submission, leading to a sharp decline in share price by over 49% [10]. Allegations in the Lawsuit - The lawsuit alleges that uniQure misrepresented the approval status of the Pivotal Study design and downplayed the likelihood of delays in the BLA timeline, resulting in misleading statements about the company's business and prospects [11].

Core Viewpoint - KDDI Corporation is under investigation for potential violations of federal securities laws, which may impact investors who have incurred losses [1] Investigation Details - The investigation is initiated by the Law Offices of Frank R. Cruz on behalf of investors [1] - KDDI announced on February 6, 2026, that it decided to postpone certain unspecified actions, raising concerns among investors [1]

Group 1 - Richtech Robotics Inc. is facing a class action lawsuit due to allegations of misleading investors about its relationship with Microsoft [1][1] - The lawsuit claims that Richtech Robotics falsely stated it had a commercial partnership with Microsoft, which was denied by Microsoft in a published article [1][1] - Following the news of the denied partnership, Richtech Robotics Class B stock price dropped over 29% within two trading days [1][1] Group 2 - The class action lawsuit allows investors who suffered substantial losses during the specified Class Period to seek appointment as lead plaintiff [1][1] - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized as a leading firm in securities fraud litigation, having recovered over $916 million for investors in 2025 alone [1][1] - The firm has a history of significant recoveries, totaling $8.4 billion for investors over the past five years [1][1]